The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | New therapies shaping the future of amyloidosis
Giampaolo Merlini, MD from Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, highlights the new types of therapeutic agents available for amyloidosis patients. Prof. Merlini provides details on a new oral proteasome inhibitor Ixazomib which has shown to be well tolerated with excellent response rate. Secondly he provides an overview on current immunotherapies specifically daratumumab, and also antibodies targeting amyloidosis deposits particularly protein serum amyloid P component (SAP) which has shown encouraging results. Recorded at the European Hematological Association (EHA) 2017 in Madrid, Spain.
